Deutsche Bank Ag\ Lipocine Inc. Transaction History

Deutsche Bank Ag\

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$0.32 - $0.77 $18,864 - $45,393	-58,953 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$0.32 - $3.15 $18,864 - $185,701	58,953 New	58,953 $22,000
Q3 2019 Nov 14, 2019	SELL	$1.79 - $3.33 $31,663 - $58,904	-17,689 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$1.43 - $2.32 $44,202 - $71,713	-30,911 Reduced 63.6%	17,689 $34,000
Q1 2019 May 15, 2019	BUY	$1.46 - $2.33 $70,956 - $113,238	48,600 New	48,600 $112,000
Q4 2018 Feb 14, 2019	SELL	$1.07 - $1.63 $8,453 - $12,877	-7,900 Closed	0 $0
Q3 2018 Dec 21, 2021	BUY	$1.31 - $1.63 $10,349 - $12,877	7,900 New	7,900 $11,000
Q3 2018 Nov 14, 2018	SELL	$1.31 - $1.63 $10,611 - $13,203	-8,100 Closed	0 $0
Q2 2018 Apr 21, 2020	BUY	$1.06 - $1.78 $8,374 - $14,062	7,900 Added 3950.0%	8,100 $10,000
Q2 2018 Aug 14, 2018	SELL	$1.06 - $1.78 $8,206 - $13,780	-7,742 Reduced 97.48%	200 $0
Q1 2018 Oct 18, 2019	BUY	$1.18 - $3.46 $9,322 - $27,334	7,900 Added 18809.52%	7,942 $12,000
Q4 2017 Feb 14, 2018	SELL	$3.36 - $4.35 $513,421 - $664,697	-152,804 Reduced 99.97%	42 $0
Q3 2017 Nov 14, 2017	BUY	$3.67 - $4.19 $560,944 - $640,424	152,846	152,846 $606,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $394M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.